KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-U01; MK-3475-U01/KEYNOTE-U01; umbrella master protocol
- Sponsors Merck Sharp & Dohme Corp.
- 18 Nov 2024 Planned number of patients changed from 825 to 1065.
- 18 Oct 2024 Planned number of patients changed from 735 to 825.
- 23 Apr 2024 Planned number of patients changed from 260 to 735.